Celeris Therapeutics is an AI-first drug development company that uses machine learning-driven methods to develop degrader drugs for currently undruggable pathogenic proteins that are related to Alzheimer's, Parkinson's, various types of cancers, and other diseases.
Celeris Therapeutics developed the Celeris One platform to build degraders faster and more efficiently. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles.
Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.
Celeris Therapeutics developed the Celeris One platform to build degraders faster and more efficiently. Celeris One leverages structure-based geometric deep learning to prioritize specific E3 ligases, design linkers, and select the most active compounds for synthesis. An in-house automated lab quickly generates experimental data for additional optimization cycles.
Celeris Therapeutics collaborates with pharma and biotech companies to jointly discover and develop small-molecule degrader medicines for all therapeutic areas. It is also developing an in-house drug pipeline. Celeris Therapeutics has offices in Menlo Park, CA, and Graz, Austria.
Focus Areas
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
